Netarsudil mesylate is a Small Molecule owned by Aerie Pharmaceuticals, and is involved in 23 clinical trials, of which 21 were completed, 1 is ongoing, and 1 is planned.
AR-13324 works by inhibiting rho kinase (ROCK) and nor-epinephrine transporter (NET). It works by lowering intraocular pressure by increasing outflow by relaxing the trabecular mesh-work. It improves blood flow to the optic nerve and prevents the cell death. Rho-kinase is an important downstream regulator of Rho-GTPase proteins, which are known to play a role in many cellular functions, including proliferation and apoptosis. Norepinephrine works as a free base and produces a significant fall in intraocular pressure and resistance to outflow. The drug candidate exhibit therapeutic intervention in the treatment of the disease by reducing damage to the optic nerve thereby preventing loss of vision or blindness. In addition AR-13324 suppresses the activity of profibrotic proteins – TGF-beta 2 and CTGF – on trabecular meshwork cells reducing intraocular pressure (IOP) in the eye. Apart from anti-fibrotic activity, the drug candidate may increase the perfusion of the trabecular meshwork with aqueous humor there by affecting the overall health of the trabecular meshwork, a tissue that helps maintain normal pressure in the eye.
The revenue for Netarsudil mesylate is expected to reach a total of $263m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Netarsudil mesylate NPV Report.
Netarsudil mesylate was originated by Duke University and is currently owned by Aerie Pharmaceuticals. Santen Pharmaceutical is the other company associated in development or marketing of Netarsudil mesylate.
Netarsudil mesylate Overview
Netarsudil mesylate (Rhopressa, Rhokiinsa) acts as an Antiglaucomas agent. It is formulated as drops solution for ophthalmic route of administration. It is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension.
The drug candidate is under development for the treatment of corneal edema associated with Fuchs Dystrophy, ocular hypertension and open-angle glaucoma.
Santen Pharmaceutical Overview
Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.
The company reported revenues of (Yen) JPY266,257 million for the fiscal year ended March 2022 (FY2022), an increase of 6.7% over FY2021. In FY2022, the company’s operating margin was 14%, compared to an operating margin of 4.9% in FY2021. In FY2022, the company recorded a net margin of 10.2%, compared to a net margin of 3.7% in FY2021. The company reported revenues of JPY63,382 million for the second quarter ended September 2022, a decrease of 3.3% over the previous quarter.
Quick View – Netarsudil mesylate
|Highest Development Stage|